HC Wainwright reiterated their buy rating on shares of Kymera Therapeutics (NASDAQ:KYMR – Free Report) in a research note published on Friday morning, Benzinga reports. They currently have a $46.00 target price on the stock. Several other analysts have also recently weighed in on KYMR. JPMorgan Chase & Co. raised their target price on shares […]
Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Free Report) has received a consensus rating of “Moderate Buy” from the twelve brokerages that are presently covering the stock, MarketBeat Ratings reports. Six analysts have rated the stock with a hold rating and six have given a buy rating to the company. The average twelve-month price target among […]
Kymera Therapeutics (NASDAQ:KYMR) Shares Down 5.5% dailypolitical.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dailypolitical.com Daily Mail and Mail on Sunday newspapers.
Kymera Therapeutics (NASDAQ:KYMR) Issues Quarterly Earnings Results, Beats Estimates By $0.04 EPS kopsource.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kopsource.com Daily Mail and Mail on Sunday newspapers.
Kymera Therapeutics (NASDAQ:KYMR – Get Free Report) posted its quarterly earnings data on Thursday. The company reported ($0.69) EPS for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.04, Briefing.com reports. The firm had revenue of $10.30 million for the quarter, compared to analyst estimates of $14.24 million. Kymera Therapeutics had a negative return […]